Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02840747 · ClinicalTrials.gov registry record
Tissue Repository: CTCL Collection Protocol
A clinical trial of Sezary Syndrome and Lymphoma, T-Cell, Cutaneous, sponsored by Columbia University.
- Recruiting
- Registry status
- 400
- Enrollment target
- 1
- Study location
NCT02840747 is a study of Sezary Syndrome and Lymphoma, T-Cell, Cutaneous that is actively recruiting participants, run by Columbia University. The registered enrollment target is 400 participants, above the 52-participant average among 13 other Sezary Syndrome trials with a reported enrollment target (669% higher). The trial reports 1 study location across 1 state.
The verdict
NCT02840747, a study of Sezary Syndrome and Lymphoma, T-Cell, Cutaneous, is actively recruiting participants, sponsored by Columbia University.
- RECRUITING
- Registry status
- 400 participants
- Enrollment target
- 1
- Study location
Study Summary
This document is a protocol for a non-interventional human research study in which the investigator hopes to better understand the changes that take place in T cells in Cutaneous T-cell lymphoma (CTCL). The purpose of this study is to establish a protocol for the collection and storage of tissue samples from patients with CTCL for future research studies. Collection and storage of tissue samples from control patients will also be carried out.
Conditions Studied
Study Locations (1)
New York
- Columbia University Irving Medical Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2016-07 |
| Est. Completion | 2026-10 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02840747
The ClinicalTrials.gov registry entry for NCT02840747 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 52-participant average among 13 other Sezary Syndrome trials with a reported enrollment target (669% higher). The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Sezary Syndrome appearing as the primary indexed condition, and to 0 interventions.
NCT02840747 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT02840747 about?
NCT02840747 is a clinical study titled "Tissue Repository: CTCL Collection Protocol". This document is a protocol for a non-interventional human research study in which the investigator hopes to better understand the changes that take place in T cells in Cutaneous T-cell lymphoma (CTCL). The purpose of this study is to establish a protocol for the collection and storage of tissue sam...
What is the current status of trial NCT02840747?
This trial is currently recruiting. The enrollment target is 400 participants. The study started on 2016-07. Estimated completion is 2026-10.
What conditions does trial NCT02840747 study?
This clinical trial studies the following conditions: Sezary Syndrome, Lymphoma, T-Cell, Cutaneous, Lymphomatoid Papulosis.
Who is sponsoring clinical trial NCT02840747?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02840747 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sezary Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
RECRUITING
-
Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients
RECRUITING · Phase 2
-
Mogamulizumab + Low-Dose Total Skin Electron Beam Tx in Mycosis Fungoides & Sézary Syndrome
RECRUITING · Phase 2
-
Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell Lymphoma
RECRUITING · Phase 2
-
Extracorporeal Photopheresis in Sezary Syndrome
RECRUITING
-
Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma
ACTIVE NOT RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.